Your browser doesn't support javascript.
loading
Pharmacokinetics of Para-Aminosalicylic Acid and Its 2 Major Metabolites: A Potential Relationship to the Development of Gastrointestinal Intolerance.
Adams, Kim T; Donald, Peter R; Abulfathi, Ahmed A; Diacon, Andreas H; Stander, Marietjie A; Reuter, Helmuth.
Afiliación
  • Adams KT; Division of Clinical Pharmacology, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa.
  • Donald PR; Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg, South Africa.
  • Abulfathi AA; Division of Clinical Pharmacology, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa.
  • Diacon AH; Task Applied Sciences, Cape Town, South Africa.
  • Stander MA; Division of Physiology, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa.
  • Reuter H; LCMS Central Analytical Facility, Stellenbosch University, Stellenbosch, South Africa.
J Clin Pharmacol ; 60(4): 489-494, 2020 04.
Article en En | MEDLINE | ID: mdl-31682027
ABSTRACT
Para-aminosalicylic acid (PAS), often the last drug remaining for treatment of drug-resistant tuberculosis, is notorious for causing gastrointestinal intolerance; however, the cause of PAS intolerance is uncertain. The objective of this study was to assess relationships between peak concentrations of PAS administered as a granular slow-release enteric coated formulation, and its metabolites acetyl-PAS and glycine-PAS, and intolerance. PAS and its metabolites were measured in 29 adult patients with drug-resistant tuberculosis at Brooklyn Hospital, Cape Town, randomized to receive granular slow-release enteric-coated PAS 4 g twice daily or 8 g once daily for 1 week, followed by the alternative regimen. Concentrations of PAS and its metabolites were determined by liquid chromatography and tandem mass spectrometry, and a visual analogue scale evaluated intolerance. Spearman's correlation test assessed the relationship between maximum plasma concentrations (Cmax ) and intolerance scores. A large interindividual variability was observed for the PAS Cmax (40.42-68.55 mg/L) following 4 g twice daily; (62.69-102.41 mg/L) for 8 g once daily and a similar wide Cmax range found for the metabolites acetyl-PAS and glycine-PAS. Twenty-six patients reported at least 1 intolerance episode, but most visual analogue scale scores clustered around 0. Significant inverse associations were found between acetyl-PAS Cmax and bloating (rho = -0.448; P = .025) and diarrhea (rho = -0.407; P = .044) for the twice-daily regimen and a similar inverse association found for glycine-PAS and diarrhea (rho = -0.412; P = .041). Plasma concentrations of the metabolites did not correlate with the occurrence of gastrointestinal symptoms, but higher metabolite concentrations correlated with lower intolerance scores; slow metabolism of PAS and its continued presence in the intestinal tract may be the main cause of intolerance.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ácido Aminosalicílico / Antituberculosos Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Female / Humans / Male País/Región como asunto: Africa Idioma: En Revista: J Clin Pharmacol Año: 2020 Tipo del documento: Article País de afiliación: Sudáfrica

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ácido Aminosalicílico / Antituberculosos Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Female / Humans / Male País/Región como asunto: Africa Idioma: En Revista: J Clin Pharmacol Año: 2020 Tipo del documento: Article País de afiliación: Sudáfrica